|
|
Article: FDA Approves Pfizer's atypical antipsychotic Geodon(R) for the Treatment of Acute Bipolar Mania; Geodon Is Not Associated With Significant Weight Gain, a Key Problem With Other Treatments - Newly Released Survey Shows Patients Gain Up to 100 Pounds on Current Bipolar Medications.
- Article from:
- PR Newswire
- Article date:
- August 23, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, Aug. 23 /PRNewswire/ -- Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Prompt and effective control of acute mania is an important goal as patients are at an increased risk for impulsive and dangerous behaviors, often requiring psychiatric hospitalization. Geodon was shown to rapidly improve acute manic symptoms and to sustain these improvements over a three-week study period. Consistent with Geodon's overall clinical profile, no significant adverse effects on weight gain ...